Skip to content
HowShorted

Avid Bioservices, Inc. short interest in 2022

In 2022, Avid Bioservices, Inc.'s disclosed short interest ran from 8.91% of shares outstanding on 14 Jan 2022 to 8.09% on 30 Dec 2022, a change of -0.82 percentage points. The year's high was 9.95% on 29 Apr 2022 and its low 7.60% on 15 Dec 2022, averaging 8.74% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.91 days on 31 Aug 2022. Full history: Avid Bioservices, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for Avid Bioservices, Inc. in 2022

2022 in figures

Start of year
8.91% (14 Jan 2022)
End of year
8.09% (30 Dec 2022)
Change
-0.82 pp
High
9.95% (29 Apr 2022)
Low
7.60% (15 Dec 2022)
Average
8.74%
Highest days to cover
12.91 (31 Aug 2022)
SEC filings marked
8

Every report in 2022

Avid Bioservices, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.91%8.79
31 Jan 20229.58%8.45
15 Feb 20229.78%10.35
28 Feb 20229.46%11.08
15 Mar 20228.84%9.2510-Q filed, results (8-K)
31 Mar 20228.40%9.66
14 Apr 20228.70%10.00
29 Apr 20229.95%10.25
13 May 20229.22%6.31
31 May 20229.68%8.75
15 Jun 20229.61%11.84
30 Jun 20228.85%7.4910-K filed, results (8-K)
15 Jul 20229.10%9.17
29 Jul 20229.46%8.93
15 Aug 20228.50%10.55
31 Aug 20227.88%12.91
15 Sep 20227.62%8.2410-Q filed, results (8-K)
30 Sep 20228.70%6.84
14 Oct 20227.82%8.39
31 Oct 20227.81%6.08
15 Nov 20228.02%7.71
30 Nov 20228.07%10.39
15 Dec 20227.60%6.4710-Q filed, results (8-K)
30 Dec 20228.09%7.50

See also: Avid Bioservices, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.